treatment resistant depression

News

R107 extended-release ketamine tablets, Douglas Pharmaceuticals

Oral ketamine set for pivotal trials in resistant depression

A mid-stage trial of oral ketamine tablets has shown promising results in treatment-resistant depression (TRD), setting up a phase 3 programme and a possible challenge to Johnson & John

R&D

Psychedelic treatments on cusp of approval, but questions re...

There is a new wave of psychedelic treatment moving through clinical trials targeting mental health conditions, and they are showing strong efficacy.

News

Cosmo Feilding Mellen, Beckley Psytech’s chief executive

Beckley builds case for its psychedelic depression therapy

Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d

News

atai invests $50m in Beckley Psytech

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica

News

Alto hits a high note with AI-driven depression therapy

Alto Neuroscience has said its therapeutic approach to depression of matching patients to drugs based on brain biomarkers has shown promise in a phase 2a trial.

News